UBS Adjusts Integra LifeSciences Price Target to $14 From $19
UBS has lowered its price target for Integra LifeSciences Holdings Corporation from $19 to $14 while maintaining a Neutral rating on the stock.
Stocks · News reference
Integra LifeSciences' $2.1B Refinancing Merits A Closer Look
Integra LifeSciences Holdings Corporation (NASDAQ:IART) completed a $2.1 billion refinancing on October 19, 2026. Its revolving credit commitment fell $700 million, from $1.3 billion to $600 million, while the new bank
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Truist Adjusts Price Target on Integra LifeSciences to $13 From $15
Truist has lowered its price target for Integra LifeSciences Holdings Corporation from $15 to $13 while maintaining a Hold rating.
JP Morgan Lowers Price Target for Integra LifeSciences
JP Morgan has reduced its price target for Integra LifeSciences Holdings Corporation from $17.00 to $14.00 per share.